Korean J Obstet Gynecol.  2010 Oct;53(10):894-904. 10.5468/kjog.2010.53.10.894.

Detection of human papillomavirus type 16 and 18 by PCR in patients with cervical neoplasia

• Park CH
• Kim JK

• KMID: 1453754
• DOI: http://doi.org/10.5468/kjog.2010.53.10.894

Abstract

OBJECTIVE
The purpose of this study was to evaluate the detection rate of human papillomavirus (HPV) DNA Test (type 16 and 18) and to investigate the clinical significance of HPV DNA test in patients with cervical neoplasia.
METHODS
Of the 708 patients aged 21~83 years who had undergone both conventional Papanicolaou cervical cytologic test and HPV DNA test by polymerase chain reaction, 383 cases underwent histologic diagnoses.
RESULTS
Of the 708 cytologic diagnoses, there were 11 positive HPV DNA test diagnoses in squamous cell carcinoma (SCC), 41 in high-grade squamous intraepithelial lesion (HSIL), 20 in low-grade squamous intraepithelial lesion (LSIL), 41 in atypical squamous cells (ASC), and 86 in negative cytology. Of the 383 histologic diagnoses, there were 24 positive HPV DNA test diagnoses in SCC, 42 in cervical intraepithelial neoplasia (CIN) 3, 12 in CIN 2, 12 in CIN 1, 7 in atypical change, and 45 in negative histology. Of the 239 patients with negative HPV DNA test, 28.5% cases showed histologic diagnoses of CIN 1 or worse lesion. Of the 46 patients with negative cytology and positive HPV DNA test, 50.0% cases showed histologic dianoses of CIN 1 or worse lesion. Pap cytology revealed sensitivity of 72.5%, specificity of 66.4%, and false negative rate of 27.5%, whereas HPV DNA test showed 57.5%, 76.7%, and 42.5%, respectively.
CONCLUSION
This study confirmed that the primary standard Pap cytology and HPV DNA test were adjunctive. Also this study showed that physicians always should not overrate Pap cytology or HPV DNA test in managing the patient with cervical neoplasia. Combined test was a very effective diagnostic method for detecting cervical neoplasia.

Keyword

Cervical neoplasia; HPV DNA test; Pap cytology; PCR

MeSH Terms

Aged
Carcinoma, Squamous Cell
Cervical Intraepithelial Neoplasia
DNA
Human Papillomavirus DNA Tests
Humans
Polymerase Chain Reaction
Sensitivity and Specificity
DNA

Figure

• 

  Fig. 1 Gel electrophoresis of human papillomavirus (HPV) 16 and 18 PCR products.

Reference

1. World Health Organization. The world health report 2004: Changing history. 2004. cited 2010 Jun 5. Geneva: World Health Organization;Available from: URL: http://www.who.int/whr/2004/en/index.html http://www.who.int/whr/2004/en/index.html.

2. International Medical Advisory Panel (IMAP). Statement on cervical cancer prevention and the potential role of HPV vaccine. IPPF Med Bull. 2007. 41:1–3.

3. Ferlay J, Bray F, Pisani P, Parkin DM. IARC CancerBase no. 5, version 2.0. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. 2004. Lyon: IARC Press.

4. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006. 24:Suppl 3. S3/11-25.

5. Park CH. False-negative results of conventional Papanicolaou cervical cytology in women with cervical conization. Korean J Gynecol Oncol. 2008. 19:40–47.

6. McCrory DC, Matcher DB, Bastian L, Datta S, Hasselblad V, Hickey J, et al. Evaluation of Cervical Cytology. Evidence Report/Technology Assessment No. 5. 1999. Rockville, MD: Agency for Health Care Policy and Research;AHCPR Publication No.99-E010.

7. Dunton CJ. New technology in Papanicolaou smear processing. Clin Obstet Gynecol. 2000. 43:410–417.

8. Reeves WC, Brinton LA, Brenes MM, Quiroz E, Rawls WE, De Britton RC. Case control study of cervical cancer in Herrera Province, Republic of Panama. Int J Cancer. 1985. 36:55–60.

9. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999. 59:6132–6136.

10. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985. 314:111–114.

11. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000. 92:690–698.

12. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189:12–19.

13. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004. 109:418–424.

14. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002. 2:342–350.

15. Wright TC Jr, Cox JT. Clinical uses of human papillomavirus (HPV) DNA testing. American Society for Colposcopy and Cervical Pathology. 2004.

16. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003. 348:518–527.

17. Lo KW, Cheung TH, Chung TK, Wang VW, Poon JS, Li JC, et al. Clinical and prognostic significance of human papillomavirus in a Chinese population of cervical cancers. Gynecol Obstet Invest. 2001. 51:202–207.

18. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004. 103:304–309.

19. Spitzer M. Human Papillomavirus: Epidemiology, natural history, and clinical sequelae. OBG Management Supplement. 2006. Suppl 18. S5–S10.

20. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005. 32:Suppl 1. S16–S24.

21. Wright TC Jr, Cox JT, Massad LS, Carlson J, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia. J Low Genit Tract Dis. 2003. 7:154–167.

22. Linder J, Zahniser D. ThinPrep Papanicolaou testing to reduce false-negative cervical cytology. Arch Pathol Lab Med. 1998. 122:139–144.

23. Gold MA. Current cervical cancer screening guidelines and impact of prophylactic HPV vaccines. New Options in HPV Prevention. OBG Management Supplement. 2006. Suppl July. S11–S17.

24. Jeon YT, Suh CS, Kim YB. Clinical significance of positive for high risk HPV and negative cytology in cervical cancer screening. J Womens Med. 2009. 2:59–62.